CYP1A2 is the major isoform responsible for paeonol O-demethylation in human liver microsomes

References

• Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64(3):659–69.
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Disposit 31(7):815–32.
   PubMed Web of Science ®Google Scholar
• Boke O, Gunes S, Kara N, Aker S, Sahin AR, Basar Y, Bagci H. (2007). Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA Cell Biol 26(8):527–31.
   PubMedGoogle Scholar
• Chou TC. (2003). Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia. Br J Pharmacol 139(6):1146–52.
   PubMedGoogle Scholar
• Chung JG. (1999). Paeonol promotion of DNA adduct formation and arylamines Nacetyltransferase activity in human colon tumour cells. Food Chem Toxicol 37(4):327–34.
   PubMedGoogle Scholar
• Corchero J, Pimprale S, Kimura S, Gonzalez JF. (2001). Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 11(1):1–6.
   PubMedGoogle Scholar
• Eaton DL, Gallagher EP, Bammler TK, Kunze KL. (1995). Role of cytochrome P4501A2 in chemical carcinogenesis: implication for human variability in expression and enzyme activity. Pharmacogenetics 5:259–74.
   PubMedGoogle Scholar
• Evans WE, McLeod HL. (2003). Pharmacogenomics — drug disposition, drug targets, and side effects. N Engl J Med 348(6):538–49.
   PubMed Web of Science ®Google Scholar
• Gjertsen FB, Solheim E, Scheline RR. (1988). Metabolism of aromatic plant ketones in rats: acetovanillone and paeonol. Xenobiotica 18(2):225–34.
   PubMedGoogle Scholar
• Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. (1994). Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54(15):4026–35.
   PubMedGoogle Scholar
• Ishiguro K, Ando T, Maeda O, Hasegawa M, Kadomatsu K, Ohmiya N, Niwa Y, Xavier R, Goto H. (2006). Paeonol attenuates TNBS-induced colitis by inhibiting NFkappaB and STAT1 transactivation. Toxicol Appl Pharmacol 217:35–42.
   PubMed Web of Science ®Google Scholar
• Iyanagi T. (2007). Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int Rev Cytol 260:35–112.
   PubMed Web of Science ®Google Scholar
• Kalow W, Tang BK. (1991). Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49(1):44–8.
   PubMedGoogle Scholar
• Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. (1997). Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Disposit 25(12):1407–15.
   PubMedGoogle Scholar
• Lewis DF, Ioannides C, Parke DV, Schulte-Hermann R. (2000). Quantitative structure–activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis. J Steroid Biochem Mol Biol 74(4):179–85.
   PubMedGoogle Scholar
• Li W, Liu Y, He YQ, Zhang JW, Gao Y, Ge GB, Liu HX, Huo H, Liu HT, Wang LM, Sun J, Wang Q, Yang L. (2008). Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica 38(12):1551–65.
   PubMedGoogle Scholar
• Lin JH, Lu AY. (2001). Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Ann Rev Pharmacol Toxicol 41:535–67.
   PubMed Web of Science ®Google Scholar
• Liu HX, Liu Y, Zhang JW, Li W, Liu HT, Yang L. (2008). UDP-glucuronosyltransferase 1A6 is the major isozyme responsible for protocatechuic aldehyde glucuronidation in human liver microsomes. Drug Metab Disposit 36(8):1562–9.
   PubMedGoogle Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–75.
   PubMed Web of Science ®Google Scholar
• Nizamutdinova IT, Oh HM, Min YN, Park SH, Lee MJ, Kim JS, Yean MH, Kang SS, Kim YS, Chang KC, Kim HJ. (2007). Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor- kappaB signaling pathways. Int Immunopharmacol 7:343–50.
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370–85.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Mathews JM. (1981). Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne-protoporphyrin IX adduct. Biochem J 195(3):761–4.
   PubMedGoogle Scholar
• Rae JM, Soukhova NV, Flockhart DA, Desta Z. (2002). Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Disposit 30(5):525–30.
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265(1):401–7.
   PubMedGoogle Scholar
• Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki M, Tang CH. (2008). Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Eur J Pharmacol 588(1):124–33.
   PubMedGoogle Scholar
• Xie Y, Zhou H, Wong YF, Xu HX, Jiang ZH, Liu L. (2008). Study on the pharmacokinetics and metabolism of paeonol in rats treated with pure paeonol and an herbal preparation containing paeonol by using HPLC-DAD-MS method. J Pharmaceut Biomed Anal 46(4):748–56.
   PubMedGoogle Scholar
• Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, Wang ZT, Yang L. (2007). Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharmaceut Sci 10(4):496–503.
   PubMedGoogle Scholar
• Zhang JW, Liu Y, Zhao JY, Wang LM, Ge GB, Gao Y, Li W, Liu HT, Liu HX, Zhang YY, Sun J, Yang L. (2008). Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Disposit 36(11):2292–8.
   PubMedGoogle Scholar
• Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, Yang L. (2009). Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39(4):283–92.
   PubMedGoogle Scholar